DK0760655T3 - Farmaceutisk flerlags doseringsform med reguleret frigivelse - Google Patents

Farmaceutisk flerlags doseringsform med reguleret frigivelse

Info

Publication number
DK0760655T3
DK0760655T3 DK95913711T DK95913711T DK0760655T3 DK 0760655 T3 DK0760655 T3 DK 0760655T3 DK 95913711 T DK95913711 T DK 95913711T DK 95913711 T DK95913711 T DK 95913711T DK 0760655 T3 DK0760655 T3 DK 0760655T3
Authority
DK
Denmark
Prior art keywords
dosage form
drug
controlled release
layer
release dosage
Prior art date
Application number
DK95913711T
Other languages
English (en)
Inventor
Pramod M Kotwal
Stephen A Howard
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Application granted granted Critical
Publication of DK0760655T3 publication Critical patent/DK0760655T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK95913711T 1994-03-23 1995-03-16 Farmaceutisk flerlags doseringsform med reguleret frigivelse DK0760655T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/217,331 US5395626A (en) 1994-03-23 1994-03-23 Multilayered controlled release pharmaceutical dosage form
PCT/US1995/003248 WO1995025506A1 (en) 1994-03-23 1995-03-16 Multilayered controlled release pharmaceutical dosage form

Publications (1)

Publication Number Publication Date
DK0760655T3 true DK0760655T3 (da) 2000-11-13

Family

ID=22810614

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95913711T DK0760655T3 (da) 1994-03-23 1995-03-16 Farmaceutisk flerlags doseringsform med reguleret frigivelse

Country Status (13)

Country Link
US (2) US5395626A (da)
EP (1) EP0760655B1 (da)
JP (1) JP4936577B2 (da)
AT (1) ATE196250T1 (da)
AU (1) AU703151B2 (da)
CA (1) CA2185893C (da)
DE (1) DE69518839T2 (da)
DK (1) DK0760655T3 (da)
ES (1) ES2151594T3 (da)
GR (1) GR3034971T3 (da)
PT (1) PT760655E (da)
WO (1) WO1995025506A1 (da)
ZA (1) ZA952343B (da)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764697B1 (en) * 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5645858A (en) * 1994-10-06 1997-07-08 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
US7008668B2 (en) * 1995-05-09 2006-03-07 Phoqus Pharmaceuticals Limited Powder coating composition for electrostatic coating of pharmaceutical substrates
PT824344E (pt) 1995-05-09 2005-09-30 Phoqus Pharmaceuticals Ltd Composicao de revestimento em po para revestimento electrostatico de substratos farmaceuticos
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
EP0811374A1 (en) 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
DE69732983T2 (de) * 1996-09-13 2006-02-16 Shionogi & Co., Ltd. Zubereitung mit verlängerter freisetzung unter verwendung einer thermischen umwandlung sowie verfahren zu deren herstellung
SE9603667D0 (sv) * 1996-10-08 1996-10-08 Astra Ab Pharmaceutical compositions
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
GB9623634D0 (en) 1996-11-13 1997-01-08 Bpsi Holdings Inc Method and apparatus for the coating of substrates for pharmaceutical use
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US6156342A (en) * 1998-05-26 2000-12-05 Andex Pharmaceuticals, Inc. Controlled release oral dosage form
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
DE29818454U1 (de) * 1998-10-15 1999-01-14 Euroceltique S.A., Luxemburg/Luxembourg Opioid-Analgetikum
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
CN101288663A (zh) * 1999-09-14 2008-10-22 史密丝克莱恩比彻姆公司 制备水性包被小球粒的方法
US6669954B2 (en) 2000-01-25 2003-12-30 John R. Crison Controlled release of drugs
CA2398555C (en) * 2000-01-27 2008-04-22 Tanabe Seiyaku Co., Ltd. Sustained release preparation and method for producing the same
GB0002305D0 (en) * 2000-02-01 2000-03-22 Phoqus Limited Power material for electrostatic application
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US6667057B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Levofloxacin antibiotic product, use and formulation thereof
US6667042B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Fluroquinilone antibiotic product, use and formulation thereof
US6632453B2 (en) 2000-02-24 2003-10-14 Advancis Pharmaceutical Corp. Ciprofoxacin-metronidazole antibiotic composition
US6669948B2 (en) 2000-02-24 2003-12-30 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6623758B2 (en) * 2000-02-24 2003-09-23 Advancis Pharmaceutical Corp. Cephalosporin-metronidazole antibiotic composition
US6638532B2 (en) 2000-02-24 2003-10-28 Advancis Pharmaceutical Corp. Tetracycline—doxycycline antibiotic composition
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6663890B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Metronidazole antibiotic product, use and formulation thereof
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6610328B2 (en) 2000-02-24 2003-08-26 Advancis Pharmaceutical Corp. Amoxicillin-clarithromycin antibiotic composition
US6730320B2 (en) 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
AU3984101A (en) 2000-02-24 2001-09-03 Advanced Pharma Inc Antibiotic and antifungal compositions
US6627222B2 (en) 2000-02-24 2003-09-30 Advancis Pharmaceutical Corp. Amoxicillin-dicloxacillin antibiotic composition
US6663891B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Erythromyacin antibiotic product, use and formulation thereof
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
AU2001257359A1 (en) 2000-04-27 2001-11-07 Verion Inc. Zero order release and temperature-controlled microcapsules and process for the preparation thereof
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
ES2228789T3 (es) * 2000-09-22 2005-04-16 Smb Technology Composicion oral de tramadol en forma de granulados para tomar una vez por dia.
US7157095B2 (en) * 2000-10-13 2007-01-02 Advancis Pharmaceutical Corporation Multiple-delayed release antifungal product, use and formulation thereof
US7105174B2 (en) * 2000-10-13 2006-09-12 Advancis Pharmaceutical Corporation Multiple-delayed release anti-neoplastic product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
FR2821747B1 (fr) * 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Suspension de telithromycine a gout masque
EA008224B1 (ru) * 2001-03-13 2007-04-27 Пенвест Фармасьютикалз Ко. Хронотерапевтические дозированные формы
CN1592609A (zh) * 2001-05-11 2005-03-09 恩德制药公司 抗滥用阿片样物质剂型
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US7157102B1 (en) * 2002-05-31 2007-01-02 Biotek, Inc. Multi-layered microcapsules and method of preparing same
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
EP1545468A4 (en) * 2002-09-20 2007-06-20 Alpharma Inc SUSTAINED RELEASE OPIOID PREPARATIONS AND METHODS OF USE
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US20040114368A1 (en) * 2002-12-13 2004-06-17 Shyu Shing Jy Light device having rotatable or movable view
GB0229258D0 (en) * 2002-12-16 2003-01-22 Boots Healthcare Int Ltd Medicinal compositions
GB2420297B (en) * 2003-06-18 2006-11-15 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
EP1648418A4 (en) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
EP1648415A4 (en) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
CA2533292C (en) * 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004263130A1 (en) * 2003-08-06 2005-02-17 Nirmal Mulye Pharmaceutical composition containing water soluble drug
WO2005016311A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) * 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1658034A4 (en) * 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
WO2005027877A1 (en) * 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EA200600598A1 (ru) * 2003-09-19 2006-08-25 Пенвест Фармасьютикалз Ко. Лекарственные формы замедленного высвобождения
US20050118267A1 (en) * 2003-09-19 2005-06-02 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
GB0330171D0 (en) * 2003-12-30 2004-02-04 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
GB0407312D0 (en) * 2004-03-31 2004-05-05 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
ES2261006B1 (es) * 2004-06-10 2007-11-01 Laboratorios Rubio, S.A. Pellet multicapa de liberacion controlada de metilfenidato.
US8715727B2 (en) * 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
US20060165769A1 (en) * 2004-09-30 2006-07-27 Hyatt John A Pharmaceutical formulations containing vitamin E TPGS molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
AU2005290829B2 (en) * 2004-10-01 2011-06-09 Nippon Zoki Pharmaceutical Co., Ltd. Solid pharmaceutical preparation
US20060073205A1 (en) * 2004-10-04 2006-04-06 Kotoe Ohta Controlled release granules comprising porous silica core
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2588295C (en) 2004-11-23 2013-10-22 Adamas Pharma, Llc Method and composition for administering an nmda receptor antagonist to a subject
CA2588296A1 (en) * 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
GB0427455D0 (en) * 2004-12-15 2005-01-19 Jagotec Ag Dosage forms
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
RU2408368C2 (ru) 2005-06-27 2011-01-10 Биовэйл Лэборэториз Интернэшнл С.Р.Л. Препараты соли бупропиона с модифицированным высвобождением
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
EP1970055B1 (en) 2005-12-29 2010-11-24 Osmotica Kereskedelmi És Szolgáltató Kft Multi-layered tablet with triple release combination
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
EP2002828B1 (en) * 2006-03-30 2019-08-07 Nippon Zoki Pharmaceutical Co. Ltd. Solid pharmaceutical preparation
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2008002567A2 (en) * 2006-06-27 2008-01-03 Alza Corporation Methods of treating conditions by sustained release administration of benzimidazole derivatives
US7638344B2 (en) * 2006-06-28 2009-12-29 Surmodics, Inc. Active agent eluting matrices with particulates
BRPI0715959A2 (pt) * 2006-08-21 2013-07-30 Jubilant Organosys Ltd composiÇço farmacÊutica de liberaÇço modificada de cloridrato de bupropion
WO2008128140A1 (en) * 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Delivery device and method for forming the same
CA2923102C (en) * 2007-08-13 2019-10-15 Omeho Life Sciences Inc. Abuse resistant drugs, method of use and method of making
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
CN102245171A (zh) * 2008-11-10 2011-11-16 株式会社爱茉莉太平洋 缓释微粒及其制备方法
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
US20100221328A1 (en) * 2008-12-31 2010-09-02 Wertz Christian F Sustained-release formulations
WO2011041414A1 (en) 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
EP2482677A1 (en) 2009-09-30 2012-08-08 The Regents of The University of California Cofactors and methods for use for individuals
AU2010325960C1 (en) 2009-12-02 2015-08-06 Adamas Pharma, Llc Amantadine compositions and methods of use
KR101243938B1 (ko) * 2010-10-19 2013-03-19 이희엽 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛
EP3466418A1 (en) 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
MX358211B (es) * 2012-07-23 2018-08-10 Landsteiner Scient S A De C V Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.
SG11201503774PA (en) 2012-11-13 2015-06-29 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
WO2014085599A1 (en) 2012-11-30 2014-06-05 Acura Pharmaceuticals, Inc. Self-regulated release of active pharmaceutical ingredient
AU2014207707B2 (en) 2013-01-15 2018-11-01 Nusirt Sciences, Inc. Treating pulmonary conditions
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
CN105228627B (zh) 2013-03-15 2018-07-13 纽斯尔特科学公司 亮氨酸和烟酸降低脂质水平
WO2014146093A2 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
MX2016011063A (es) 2014-02-27 2016-11-30 Nusirt Sciences Inc Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica.
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
CA3001495C (en) * 2014-11-03 2021-07-20 Solipharma Llc Formulations of dabigatran etexilate or dabigatran etexilate salts and preparation methods thereof
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
WO2017058436A1 (en) * 2015-09-30 2017-04-06 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
CN106176683B (zh) * 2016-08-31 2019-04-16 贵州益康制药有限公司 一种盐酸曲马多缓释胶囊及其制备方法和用途
US9707217B1 (en) 2017-02-03 2017-07-18 Osmotica Kereskedelmi Es Szolgaltato Kft Dose-dumping resistant controlled release dosage form
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
JP6482604B2 (ja) * 2017-06-22 2019-03-13 教裕 南郷 外皮内溶解型ニードル及びニードル装置
WO2019087084A1 (en) 2017-11-02 2019-05-09 Eman Biodiscoveries Sd. Bhd. Extract of orthosiphon stamineus, formulations, and uses thereof
WO2020067887A1 (en) 2018-09-24 2020-04-02 Erasmus University Medical Center Rotterdam Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN116473942B (zh) * 2022-01-13 2026-05-05 山东新时代药业有限公司 一种氯雷他定缓释胶囊及其制备方法
WO2025111679A1 (pt) * 2023-11-30 2025-06-05 Prati, Donaduzzi & Cia Ltda Forma farmacêutica oral para liberação bifásica, composta por um sistema multiparticulado, processo para preparação da mesma e uso terapêutico da forma oral

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB793808A (en) * 1954-07-22 1958-04-23 Frank Mario Bardani Sustained action pill
JPS5835110A (ja) * 1981-08-28 1983-03-01 Tetsuo Kato 徐放性マイクロカプセル
ZA838033B (en) * 1982-11-01 1984-06-27 Merrell Dow Pharma Sustained release solid dosage forms having non-uniform distribution of active ingredient
JPS5982311A (ja) * 1982-11-04 1984-05-12 Shionogi & Co Ltd セフアレキシン持効性製剤
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4917899A (en) * 1983-12-22 1990-04-17 Elan Corporation Plc Controlled absorption diltiazem formulation
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
EP0225085A1 (en) * 1985-11-13 1987-06-10 ELAN CORPORATION, Plc Controlled absorption pharmaceutical formulation
JPS62226926A (ja) * 1986-03-27 1987-10-05 Teisan Seiyaku Kk 持続性複合顆粒剤
JPH0236571B2 (ja) * 1986-04-11 1990-08-17 Otsuka Pharma Co Ltd Jizokuseiseizai
IT1197316B (it) * 1986-10-01 1988-11-30 Proter Spa Formulazione galenica ad uso orale di derivati della reina a lento rilascio per impiego terapeutico
JPS63319134A (ja) * 1987-06-22 1988-12-27 スリー　エス．テクノロジーズ　ベスローテン　ベノートスハップ 水供給用シ−ト
US4891223A (en) * 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
JP2643222B2 (ja) * 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
ATE114472T1 (de) * 1989-09-21 1994-12-15 American Cyanamid Co System des typs ''einmal täglich'' zur gepulsten minocyclinabgabe.
JP3090975B2 (ja) * 1991-05-13 2000-09-25 塩野義製薬株式会社 マルチリザ−バ−型徐放性顆粒剤およびその製法
ES2073301T3 (es) * 1991-05-20 1995-08-01 Marion Laboratories Inc Composicion multi-capa de liberacion controlada.
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient

Also Published As

Publication number Publication date
ZA952343B (en) 1996-09-23
MX9604300A (es) 1998-05-31
JPH09510709A (ja) 1997-10-28
US5474786A (en) 1995-12-12
CA2185893A1 (en) 1995-09-28
AU1999595A (en) 1995-10-09
ES2151594T3 (es) 2001-01-01
PT760655E (pt) 2000-12-29
DE69518839D1 (de) 2000-10-19
US5395626A (en) 1995-03-07
GR3034971T3 (en) 2001-02-28
EP0760655A1 (en) 1997-03-12
WO1995025506A1 (en) 1995-09-28
ATE196250T1 (de) 2000-09-15
EP0760655B1 (en) 2000-09-13
DE69518839T2 (de) 2001-02-22
AU703151B2 (en) 1999-03-18
CA2185893C (en) 2009-05-26
JP4936577B2 (ja) 2012-05-23

Similar Documents

Publication Publication Date Title
ZA952343B (en) Multilayered controlled release pharmaceutical dosage form
NO172422C (no) Fremgangsmaate for fremstilling av en medikamentholdig flerlagsgranul
DE69817587D1 (de) Aus einer vielzahl von kleineinheiten aufgebaute brausedosisform
HK1038701A1 (zh) 口脈冲劑量藥物釋放系統
ATE213629T1 (de) Milnacipranhaltige darreichungsform mit verzögerter wirkstoffabgabe
GR1002564B (el) Στερεα απο του στοματος χορηγουμενη φαρμακευτικη μορφη δοσιμετρησεως προγραμματισμενου ρυθμου απελευθερωσεως.
ATE216220T1 (de) Osmotische darreichungsform mit zwei mantelschichten
ATE165734T1 (de) Arzneitablette, die befähigt ist, einen oder mehrere wirkstoffe mit unterschiedlichen abgaberaten freizusetzen
CA2375714A1 (en) Delayed total release two pulse gastrointestinal drug delivery system
AR005282A1 (es) Composición farmacéutica oral en la forma de un comprimido de unidades múltiples, uso de la misma para la preparación de medicamnetos, y procedimiento para su manufactura.
AR002598A1 (es) Inhalador para la administración de medicamentos desde envases blister
CA2214033A1 (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent
DE69814122D1 (de) Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt
DK0750494T3 (da) Hydrofobe lægemiddelafgivelsessystemer
CA2137017A1 (en) Controlled release pharmaceutical tablet having lenticular form
ES8607008A1 (es) Procedimiento para la preparar una tableta farmaceutica para procurar una liberacion sostenidad de medicamento.
BR9815248A (pt) Sistema monolìtico contendo um ou mais medicamentos, consistindo de três camadas com diferentes mecanismos de liberação
DE69425589D1 (de) Kombiniertes antipyretisches und analgetisches arzneimittel
WO1997020582A3 (en) Transdermal patch for comparative evaluations
ATE290854T1 (de) Carbamazepinformulierung mit verzögerter freigabe
GEP20022629B (en) Sustained-Release Microgranules Containing Diltiazem As The Active Principle and Gelatinous Capsule Containing the Same
IT1196190B (it) Forma farmaceutica solida orale ad azione sequenziale per la somministrazione di farmaci ad effetto collaterale ulcerogeno